Adagrasib Improves PFS Over Docetaxel in Patients with Previously Treated KRASG12C-mutated NSCLC By Ogkologos - August 20, 2025 344 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the KRYSTAL-12 study Source RELATED ARTICLESMORE FROM AUTHOR EMA Recommends Extending Indications for Pembrolizumab and Adopted a New Pharmaceutical Form Along with a New Route of Administration FDA Approves Pembrolizumab and Berahyaluronidase alfa-pmph for Subcutaneous Injection Study presents an AI-guided approach to target cancer antigens MOST POPULAR Kid Friendly Meals October 2, 2020 Woman Who Lost Husband to Male Breast Cancer Goes on Road... September 16, 2021 EMA Recommends Extension of Indications for Enzalutamide April 2, 2021 Gym Offers Free Membership & Support To Those Struggling With Addiction October 25, 2021 Load more HOT NEWS Brentuximab Approved for Initial Treatment of Advanced Hodgkin Lymphoma Telehealth Can Save People with Cancer Time, Travel, and Money Adjuvant Atezolizumab Plus Bevacizumab Improves RFS Among Patients at High Risk... T-DM1 is Active and Well Tolerated in Patients with HER2-positive Metastatic...
